Showing results (281-290 of 293) with videos related to
Sort By:
Pageof 30
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.Nature Medicine|July 1, 2026
Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infectionLoukas Papargyris, Jiayun Xu, Claire Broderick, et al.Annals of the New York Academy of Sciences|January 14, 2022
Innovative vaccine approaches-a Keystone Symposia reportJennifer Cable, Rino Rappuoli, Elizabeth J Klemm, et al.Nature Communications|November 30, 2024
SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infectionsJoshua Rosenheim, Rishi K Gupta, Clare Thakker, et al.Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.Nature Medicine|September 23, 2024
Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reductionGreta K Wood, Brendan F Sargent, Zain-Ul-Abideen Ahmad, et al.Biologicals : Journal of the International Association of Biological Standardization|January 17, 2025
Regulatory workshop on standardisation of clinical procedures, endpoints and data robustness of human challenge studies - A stakeholder meeting reportIrina Meln, Victor Cnossen, Nicoletta Corti, et al.Nature|June 19, 2024
Human SARS-CoV-2 challenge uncovers local and systemic response dynamicsRik G H Lindeboom, Kaylee B Worlock, Lisa M Dratva, et al.Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.Nature Immunology|April 8, 2024
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of diseaseFelicity Liew, Claudia Efstathiou, Sara Fontanella, et al.Pageof 30